Search

Your search keyword '"Hoyer, BF"' showing total 184 results
Start Over Author "Hoyer, BF"
184 results on '"Hoyer, BF"'

4. Durchbruchinfektionen bei vollständig geimpften Patienten mit entzündlich-rheumatischen Erkrankungen - Daten aus dem COVID19-Rheuma.de-Register

Author

Hasseli, R, Hoyer, BF, Huppke, L, Lorenz, HM, Pfeil, A, Regierer, A, Richter, J, Schmeiser, T, Strangfeld, A, Voll, R, Krause, A, Schulze-Koops, H, Specker, C, Müller-Ladner, U, Hasseli, R, Hoyer, BF, Huppke, L, Lorenz, HM, Pfeil, A, Regierer, A, Richter, J, Schmeiser, T, Strangfeld, A, Voll, R, Krause, A, Schulze-Koops, H, Specker, C, and Müller-Ladner, U

Published
2022

7. Das Gemeinsame Vaskulitis-Register im deutschsprachigen Raum (GeVas) - eine Subgruppenanalyse der 131 RZA-Patienten

Author

Wallmeier, P, Arnold, S, Schubach, F, Ihorst, G, Dörnbrack, K, Aries, PM, Bergner, R, Bremer, JP, Görl, N, Hellmich, B, Henes, J, Hoyer, BF, Kangowski, A, Kötter, I, Metzler, C, Müller-Ladner, U, Schaier, M, Schönermark, U, Thiel, J, Unger, L, Venhoff, N, Weinmann-Menke, J, Petersen, J, Lamprecht, P, Iking-Konert, C, Wallmeier, P, Arnold, S, Schubach, F, Ihorst, G, Dörnbrack, K, Aries, PM, Bergner, R, Bremer, JP, Görl, N, Hellmich, B, Henes, J, Hoyer, BF, Kangowski, A, Kötter, I, Metzler, C, Müller-Ladner, U, Schaier, M, Schönermark, U, Thiel, J, Unger, L, Venhoff, N, Weinmann-Menke, J, Petersen, J, Lamprecht, P, and Iking-Konert, C

Published
2022

8. Krankheitsaktivität und Schmerzen von Patienten mit rheumatologischen Erkrankungen wurden durch die COVID-19-Pandemie nicht beeinflusst – Interims-Analyse aus der Deutschen Rheuma-COVID19-Patienten-Befragung

Author

Hoyer, BF, Hasseli, R, Müller-Ladner, U, Schmeiser, T, Krause, A, Lorenz, HM, Pfeil, A, Regierer, A, Richter, J, Schulze-Koops, H, Strangfeld, A, Voll, R, and Specker, C

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die derzeitige Pandemie ist insbesondere für Patienten mit chronisch-entzündlichen Erkrankungen und ihre Ärzte eine schwierige Phase: Lockdowns, steigende Infektionsraten und neue Mutationen sorgen für eine große Verunsicherung. Die psychosoziale Belastung und Versorgungsprobleme[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

9. Phenotypic analysis of circulating plasma cells after immunization with anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory diseases

Author

Ciripoi, MS, Geisen, UM, Vullriede, L, Reid, HM, Berner, DK, Tran, F, Sümbül, M, Schaffarzyk, A, Schirmer, JH, Zeuner, R, Friedrichs, A, Steinbach, A, Gerdes, S, Bacher, P, Schreiber, S, and Hoyer, BF

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Introduction: Plasma cells and plasmablasts (PCs) in the peripheral blood have been shown to exhibit a phenotype different to homoeostatic PC populations of the blood in response to vaccinations, i.e. after tetanus vaccinations. These cells present with a phenotype of newly activated plasmablasts and[for full text, please go to the a.m. URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

10. Does TNF-inhibition decrease the risk of severe COVID-19 in RMD-patients?

Author

Hasseli, R, Hoyer, BF, Lorenz, HM, Pfeil, A, Regierer, A, Richter, J, Schmeiser, T, Strangfeld, A, Voll, R, Specker, C, Schulze-Koops, H, Müller-Ladner, U, and Krause, A

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Introduction: Patients with rheumatic and musculoskeletal diseases (RMD) might have an increased risk for infection due to their immunomodulatory treatment. The aim of this study was to assess courses of RMD-patients treated with TNF-inhibitors (TNF-I) included in the German COVID-19 registry. Methods:[for full text, please go to the a.m. URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

11. Detection of SARS-CoV2-specific antibody-releasing plasma cells using fluorospot technology in patients after mRNA vaccination

Author

Vullriede, L, Geisen, U, Ciripoi, M, Reid, HM, Berner, D, Tran, F, Sümbül, M, Schaffarzyk, A, Schirmer, J, Zeuner, R, Friedrichs, A, Steinbach, A, Gerdes, S, Bacher, P, Schreiber, S, and Hoyer, BF

Subjects
body regions, ddc: 610, fungi, chemical and pharmacologic phenomena, 610 Medical sciences, Medicine, skin and connective tissue diseases
Abstract

Introduction: mRNA vaccinations are a new technology introduced in the context of the current SARS-CoV2 pandemic. As the immune response to SARS-CoV2 is not fully understood, tools to measure the specific immune response are urgently needed. Elispot technology is able to demonstrate the functionality[for full text, please go to the a.m. URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

12. Immunosuppressive profile of deadly courses of COVID-19 in a large-scale real-life rheumatic cohort

Author

Hasseli, R, Hoyer, BF, Krause, A, Lorenz, HM, Pfeil, A, Regierer, A, Richter, J, Schmeiser, T, Strangfeld, A, Voll, R, Müller-Ladner, U, Schulze-Koops, H, and Specker, C

Subjects
musculoskeletal diseases, ddc: 610, 610 Medical sciences, Medicine, skin and connective tissue diseases
Abstract

Introduction: Patients with inflammatory rheumatic diseases (IRD) are routinely treated with disease-modifying anti-rheumatic drugs (DMARDs). After more than a year of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, still few data are available on the association of DMARDs with[for full text, please go to the a.m. URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

18. Outcome of SARS-CoV-2 infection in patients with rheumatoid arthritis under treatment with Janus kinase inhibitors compared to etanercept

Author

Hasseli, R, Hoyer, BF, Krause, A, Lorenz, HM, Pfeil, A, Regierer, A, Richter, J, Schmeiser, T, Strangfeld, A, Schulze-Koops, H, Voll, R, Specker, C, Müller-Ladner, U, Hasseli, R, Hoyer, BF, Krause, A, Lorenz, HM, Pfeil, A, Regierer, A, Richter, J, Schmeiser, T, Strangfeld, A, Schulze-Koops, H, Voll, R, Specker, C, and Müller-Ladner, U

Published
2021

19. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Author

Sattui, SE, Liew, JW, Kennedy, K, Sirotich, E, Putman, M, Moni, TT, Akpabio, A, Alpizar-Rodriguez, D, Berenbaum, F, Bulina, I, Conway, R, Singh, AD, Duff, E, Durrant, KL, Gheita, TA, Hill, CL, Howard, RA, Hoyer, BF, Hsieh, E, El Kibbi, L, Kilian, A, Kim, AH, Liew, DFL, Lo, C, Miller, B, Mingolla, S, Nudel, M, Palmerlee, CA, Singh, JA, Singh, N, Ugarte-Gil, MF, Wallace, J, Young, KJ, Bhana, S, Costello, W, Grainger, R, Machado, PM, Robinson, PC, Sufka, P, Wallace, ZS, Yazdany, J, Harrison, C, Larche, M, Levine, M, Foster, G, Thabane, L, Rider, LG, Hausmann, JS, Simard, JF, Sparks, JA, Sattui, SE, Liew, JW, Kennedy, K, Sirotich, E, Putman, M, Moni, TT, Akpabio, A, Alpizar-Rodriguez, D, Berenbaum, F, Bulina, I, Conway, R, Singh, AD, Duff, E, Durrant, KL, Gheita, TA, Hill, CL, Howard, RA, Hoyer, BF, Hsieh, E, El Kibbi, L, Kilian, A, Kim, AH, Liew, DFL, Lo, C, Miller, B, Mingolla, S, Nudel, M, Palmerlee, CA, Singh, JA, Singh, N, Ugarte-Gil, MF, Wallace, J, Young, KJ, Bhana, S, Costello, W, Grainger, R, Machado, PM, Robinson, PC, Sufka, P, Wallace, ZS, Yazdany, J, Harrison, C, Larche, M, Levine, M, Foster, G, Thabane, L, Rider, LG, Hausmann, JS, Simard, JF, and Sparks, JA

Abstract

BACKGROUND: We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. METHODS: From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. RESULTS: We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. CONCLUSION: Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

Published
2021

20. B- und T-Zell Populationen in Patienten mit Riesenzellarteriitis und Polymyalgia rheumatica zeigen eine gestörte Homöostase im peripheren Blut

Author

Dörr, J, Geisen, U, Schaffarzyk, A, and Hoyer, BF

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Riesenzellarteriitis (RZA) oder auch Arteriitis Temporalis gehört zu den häufigsten systemischen Vaskulitiden bei Patienten ab dem 50. Lebensjahr und ist in etwa der Hälfte der Fälle mit einer Polymyalgia rheumatica (PMR) assoziiert. Bis heute ist die Ätiologie[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2020, 48. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 34. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)

Published
2020
Full Text
View/download PDF

21. Zytokinsturm bei COVID-19: Zellulär das Gleiche wie systematische Autoimmunität?

Author

Hoyer, BF, Geisen, U, Dörr, J, Schaffarzyk, A, Bahmer, T, Berner, D, Schirmer, J, and Schreiber, S

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Im Rahmen einer COVID19-Erkrankung durch Sars-Cov2 finden sich Veränderungen im Immunsystem, die der Immunreaktion einer aktiven systemischen Autoimmunerkrankung ähneln. So befinden sich zahlreiche Medikamente, die in der Therapie systemischer Autoimmunerkrankungen eingesetzt werden,[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2020, 48. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 34. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)

Published
2020
Full Text
View/download PDF

22. Deutsches COVID-19 Register für Patienten mit entzündlich-rheumatischen Erkrankungen

Author

Hasseli, R, Müller-Ladner, U, Richter, J, Regierer, A, Hoyer, BF, Voll, R, Schmeiser, T, Lorenz, HM, Strangfeld, A, Krause, A, Pfeil, A, Schulze-Koops, H, and Specker, C

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Patienten mit entzündlich-rheumatischen Erkrankungen weisen eine Fehlregulation des Immunsystems auf. Zudem können immunmodulierende und immunsuppressive Therapien den Infektionsverlauf beeinflussen. Die aktuelle SARS-CoV-2 Pandemie stellt für die Rheumatologie daher eine [zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2020, 48. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 34. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)

Published
2020
Full Text
View/download PDF

23. Evaluation von Patienten mit entzündlich-rheumatischen Erkrankungen unter Immunsuppressiva und ihrer Haltung zur Medikation im zeitlichen Verlauf der Covid-19 Pandemie

Author

Schmeiser, T, Broll, M, Dormann, A, Fräbel, C, Heinmüller, CJ, Hermann, W, Hoyer, BF, Keil, F, Müller-Ladner, U, Özden, F, Pfeiffer, U, Saech, J, Schwarting, A, Sluszniak, M, Specker, C, Stapfer, G, Steinchen, N, Steinmüller, M, Storck-Mueller, K, Strunk, J, Thiele, A, Triantafyllias, K, Vagedes, D, Wassenberg, S, Wilden, E, and Hasseli, R

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Seit 11.03.2020 spricht die WHO von einer Coronavirus Pandemie. Verursacht wird die Coronaviruserkrankung (COVID-19) durch das SARS-CoV-2 Virus. Die Erkrankung manifestiert sich als Infektion der Atemwege mit den Leitsymptomen Fieber und Husten. Bei 81% Patienten ist der Verlauf mild,[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2020, 48. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 34. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)

Published
2020
Full Text
View/download PDF

24. Statusbericht des GeVas Registers: Gemeinsames Vaskulitis Register im deutschsprachigen Raum zur prospektiven Auswertung des Langzeitverlaufs von Vaskulitis-Patienten

Author

Wallmeier, P, Iking-Konert, C, Adler, S, De Groot, K, Hellmich, B, Hoyer, BF, Ihorst, G, Kaufmann, M, Magnus, T, Müller-Ladner, U, Rech, J, Schulze-Koops, H, Venhoff, N, Villiger, P, Schubach, F, Lamprecht, P, Wallmeier, P, Iking-Konert, C, Adler, S, De Groot, K, Hellmich, B, Hoyer, BF, Ihorst, G, Kaufmann, M, Magnus, T, Müller-Ladner, U, Rech, J, Schulze-Koops, H, Venhoff, N, Villiger, P, Schubach, F, and Lamprecht, P

Published
2020

25. Alter, Komorbiditäten und Therapie mit Glukokortikoiden sind Risikofaktoren für eine COVID-19-bedingte Hospitalisierung: erste Ergebnisse aus dem deutschen COVID-19-Rheuma-Register

Author

Regierer, A, Hasseli, R, Müller-Ladner, U, Hoyer, BF, Krause, A, Lorenz, HM, Pfeil, A, Richter, J, Schmeiser, T, Schulze-Koops, H, Strangfeld, A, Voll, R, Specker, C, Regierer, A, Hasseli, R, Müller-Ladner, U, Hoyer, BF, Krause, A, Lorenz, HM, Pfeil, A, Richter, J, Schmeiser, T, Schulze-Koops, H, Strangfeld, A, Voll, R, and Specker, C

Published
2020

27. Untersuchung des psychosozialen Einflusses der Corona-Pandemie auf rheumatologische Patienten in einer prospektiven, longitudinalen Befragung

Author

Hasseli, R, Schmeiser, T, Hermann, C, Kappesser, J, Pfeiffer, S, Müller-Ladner, U, Richter, J, Regierer, A, Voll, R, Lorenz, HM, Strangfeld, A, Krause, A, Pfeil, A, Schulze-Koops, H, Specker, C, Hoyer, BF, Hasseli, R, Schmeiser, T, Hermann, C, Kappesser, J, Pfeiffer, S, Müller-Ladner, U, Richter, J, Regierer, A, Voll, R, Lorenz, HM, Strangfeld, A, Krause, A, Pfeil, A, Schulze-Koops, H, Specker, C, and Hoyer, BF

Published
2020

28. 'Problemzone Aquarium': Schwere atypische Mycobakterose unter Immunsuppression durch Mycophenolat

Author

Zeuner, R, Steinbach, A, Mrowietz, U, Bertolini, R, Both, M, and Hoyer, BF

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Ein 39-Jahre alter Mann stellte sich mit einer Weichteilschwellung des linken Zeigefingers vor. Er wurde bei schwerem Lupus erythematodes (Arthritis, Serositis mit Pericarditis, ANA, ds-DNA-Antikörper Nachweis und C3-Hypokomplementämie) mit Mycophenolat und Hydroxychloroquin behandelt. Der[zum vollständigen Text gelangen Sie über die oben angegebene URL], 47. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 33. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 29. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2019
Full Text
View/download PDF

29. Therapie mit Interleukin-6-Blockadern führt zum signifikanten Abfall des Serumkomplementspiegels (C3/C4) und ist unabhängig vom klinischen Ansprechen

Author

Steinbach, A, Zeuner, R, Schreiber, S, Schröder, JO, and Hoyer, BF

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Interleukin 6 ist ein Zytokin mit vielfältigen biologischen Aktivitäten, das eine Schlüsselrolle bei der Akute-Phase-Reaktion des Immunsystems und bei der Unterhaltung und Chronifizierung von inflammatorischer Erkrankungen spielt. Eines der gegen Interleukin 6 gerichteteten[zum vollständigen Text gelangen Sie über die oben angegebene URL], 47. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 33. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 29. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2019
Full Text
View/download PDF

32. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Author

Cossarizza, A, Chang, H-D, Radbruch, A, Acs, A, Adam, D, Adam-Klages, S, Agace, WW, Aghaeepour, N, Akdis, M, Allez, M, Almeida, LN, Alvisi, G, Anderson, G, Andrae, I, Annunziato, F, Anselmo, A, Bacher, P, Baldari, CT, Bari, S, Barnaba, V, Barros-Martins, J, Battistini, L, Bauer, W, Baumgart, S, Baumgarth, N, Baumjohann, D, Baying, B, Bebawy, M, Becher, B, Beisker, W, Benes, V, Beyaert, R, Blanco, A, Boardman, DA, Bogdan, C, Borger, JG, Borsellino, G, Boulais, PE, Bradford, JA, Brenner, D, Brinkman, RR, Brooks, AES, Busch, DH, Buescher, M, Bushnell, TP, Calzetti, F, Cameron, G, Cammarata, I, Cao, X, Cardell, SL, Casola, S, Cassatella, MA, Cavani, A, Celada, A, Chatenoud, L, Chattopadhyay, PK, Chow, S, Christakou, E, Cicin-Sain, L, Clerici, M, Colombo, FS, Cook, L, Cooke, A, Cooper, AM, Corbett, AJ, Cosma, A, Cosmi, L, Coulie, PG, Cumano, A, Cvetkovic, L, Dang, VD, Dang-Heine, C, Davey, MS, Davies, D, De Biasi, S, Del Zotto, G, Dela Cruz, GV, Delacher, M, Della Bella, S, Dellabona, P, Deniz, G, Dessing, M, Di Santo, JP, Diefenbach, A, Dieli, F, Dolf, A, Doerner, T, Dress, RJ, Dudziak, D, Dustin, M, Dutertre, C-A, Ebner, F, Eckle, SBG, Edinger, M, Eede, P, Ehrhardt, GRA, Eich, M, Engel, P, Engelhardt, B, Erdei, A, Esser, C, Everts, B, Evrard, M, Falk, CS, Fehniger, TA, Felipo-Benavent, M, Ferry, H, Feuerer, M, Filby, A, Filkor, K, Fillatreau, S, Follo, M, Foerster, I, Foster, J, Foulds, GA, Frehse, B, Frenette, PS, Frischbutter, S, Fritzsche, W, Galbraith, DW, Gangaev, A, Garbi, N, Gaudilliere, B, Gazzinelli, RT, Geginat, J, Gerner, W, Gherardin, NA, Ghoreschi, K, Gibellini, L, Ginhoux, F, Goda, K, Godfrey, DI, Goettlinger, C, Gonzalez-Navajas, JM, Goodyear, CS, Gori, A, Grogan, JL, Grummitt, D, Gruetzkau, A, Haftmann, C, Hahn, J, Hammad, H, Haemmerling, G, Hansmann, L, Hansson, G, Harpur, CM, Hartmann, S, Hauser, A, Hauser, AE, Haviland, DL, Hedley, D, Hernandez, DC, Herrera, G, Herrmann, M, Hess, C, Hoefer, T, Hoffmann, P, Hogquist, K, Holland, T, Hollt, T, Holmdahl, R, Hombrink, P, Houston, JP, Hoyer, BF, Huang, B, Huang, F-P, Huber, JE, Huehn, J, Hundemer, M, Hunter, CA, Hwang, WYK, Iannone, A, Ingelfinger, F, Ivison, SM, Jaeck, H-M, Jani, PK, Javega, B, Jonjic, S, Kaiser, T, Kalina, T, Kamradt, T, Kaufmann, SHE, Keller, B, Ketelaars, SLC, Khalilnezhad, A, Khan, S, Kisielow, J, Klenerman, P, Knopf, J, Koay, H-F, Kobow, K, Kolls, JK, Kong, WT, Kopf, M, Korn, T, Kriegsmann, K, Kristyanto, H, Kroneis, T, Krueger, A, Kuehne, J, Kukat, C, Kunkel, D, Kunze-Schumacher, H, Kurosaki, T, Kurts, C, Kvistborg, P, Kwok, I, Landry, J, Lantz, O, Lanuti, P, LaRosa, F, Lehuen, A, LeibundGut-Landmann, S, Leipold, MD, Leung, LYT, Levings, MK, Lino, AC, Liotta, F, Litwin, V, Liu, Y, Ljunggren, H-G, Lohoff, M, Lombardi, G, Lopez, L, Lopez-Botet, M, Lovett-Racke, AE, Lubberts, E, Luche, H, Ludewig, B, Lugli, E, Lunemann, S, Maecker, HT, Maggi, L, Maguire, O, Mair, F, Mair, KH, Mantovani, A, Manz, RA, Marshall, AJ, Martinez-Romero, A, Martrus, G, Marventano, I, Maslinski, W, Matarese, G, Mattioli, AV, Maueroder, C, Mazzoni, A, McCluskey, J, McGrath, M, McGuire, HM, McInnes, IB, Mei, HE, Melchers, F, Melzer, S, Mielenz, D, Miller, SD, Mills, KHG, Minderman, H, Mjosberg, J, Moore, J, Moran, B, Moretta, L, Mosmann, TR, Mueller, S, Multhoff, G, Munoz, LE, Munz, C, Nakayama, T, Nasi, M, Neumann, K, Ng, LG, Niedobitek, A, Nourshargh, S, Nunez, G, O'Connor, J-E, Ochel, A, Oja, A, Ordonez, D, Orfao, A, Orlowski-Oliver, E, Ouyang, W, Oxenius, A, Palankar, R, Panse, I, Pattanapanyasat, K, Paulsen, M, Pavlinic, D, Penter, L, Peterson, P, Peth, C, Petriz, J, Piancone, F, Pickl, WF, Piconese, S, Pinti, M, Pockley, AG, Podolska, MJ, Poon, Z, Pracht, K, Prinz, I, Pucillo, CEM, Quataert, SA, Quatrini, L, Quinn, KM, Radbruch, H, Radstake, TRDJ, Rahmig, S, Rahn, H-P, Rajwa, B, Ravichandran, G, Raz, Y, Rebhahn, JA, Recktenwald, D, Reimer, D, Reis e Sousa, C, Remmerswaal, EBM, Richter, L, Rico, LG, Riddell, A, Rieger, AM, Robinson, JP, Romagnani, C, Rubartelli, A, Ruland, J, Saalmueller, A, Saeys, Y, Saito, T, Sakaguchi, S, Sala-de-Oyanguren, F, Samstag, Y, Sanderson, S, Sandrock, I, Santoni, A, Sanz, RB, Saresella, M, Sautes-Fridman, C, Sawitzki, B, Schadt, L, Scheffold, A, Scherer, HU, Schiemann, M, Schildberg, FA, Schimisky, E, Schlitzer, A, Schlosser, J, Schmid, S, Schmitt, S, Schober, K, Schraivogel, D, Schuh, W, Schueler, T, Schulte, R, Schulz, AR, Schulz, SR, Scotta, C, Scott-Algara, D, Sester, DP, Shankey, TV, Silva-Santos, B, Simon, AK, Sitnik, KM, Sozzani, S, Speiser, DE, Spidlen, J, Stahlberg, A, Stall, AM, Stanley, N, Stark, R, Stehle, C, Steinmetz, T, Stockinger, H, Takahama, Y, Takeda, K, Tan, L, Tarnok, A, Tiegs, G, Toldi, G, Tornack, J, Traggiai, E, Trebak, M, Tree, TIM, Trotter, J, Trowsdale, J, Tsoumakidou, M, Ulrich, H, Urbanczyk, S, van de Veen, W, van den Broek, M, van der Pol, E, Van Gassen, S, Van Isterdael, G, van Lier, RAW, Veldhoen, M, Vento-Asturias, S, Vieira, P, Voehringer, D, Volk, H-D, von Borstel, A, von Volkmann, K, Waisman, A, Walker, RV, Wallace, PK, Wang, SA, Wang, XM, Ward, MD, Ward-Hartstonge, KA, Warnatz, K, Warnes, G, Warth, S, Waskow, C, Watson, JV, Watzl, C, Wegener, L, Weisenburger, T, Wiedemann, A, Wienands, J, Wilharm, A, Wilkinson, RJ, Willimsky, G, Wing, JB, Winkelmann, R, Winkler, TH, Wirz, OF, Wong, A, Wurst, P, Yang, JHM, Yang, J, Yazdanbakhsh, M, Yu, L, Yue, A, Zhang, H, Zhao, Y, Ziegler, SM, Zielinski, C, Zimmermann, J, Zychlinsky, A, Cossarizza, A, Chang, H-D, Radbruch, A, Acs, A, Adam, D, Adam-Klages, S, Agace, WW, Aghaeepour, N, Akdis, M, Allez, M, Almeida, LN, Alvisi, G, Anderson, G, Andrae, I, Annunziato, F, Anselmo, A, Bacher, P, Baldari, CT, Bari, S, Barnaba, V, Barros-Martins, J, Battistini, L, Bauer, W, Baumgart, S, Baumgarth, N, Baumjohann, D, Baying, B, Bebawy, M, Becher, B, Beisker, W, Benes, V, Beyaert, R, Blanco, A, Boardman, DA, Bogdan, C, Borger, JG, Borsellino, G, Boulais, PE, Bradford, JA, Brenner, D, Brinkman, RR, Brooks, AES, Busch, DH, Buescher, M, Bushnell, TP, Calzetti, F, Cameron, G, Cammarata, I, Cao, X, Cardell, SL, Casola, S, Cassatella, MA, Cavani, A, Celada, A, Chatenoud, L, Chattopadhyay, PK, Chow, S, Christakou, E, Cicin-Sain, L, Clerici, M, Colombo, FS, Cook, L, Cooke, A, Cooper, AM, Corbett, AJ, Cosma, A, Cosmi, L, Coulie, PG, Cumano, A, Cvetkovic, L, Dang, VD, Dang-Heine, C, Davey, MS, Davies, D, De Biasi, S, Del Zotto, G, Dela Cruz, GV, Delacher, M, Della Bella, S, Dellabona, P, Deniz, G, Dessing, M, Di Santo, JP, Diefenbach, A, Dieli, F, Dolf, A, Doerner, T, Dress, RJ, Dudziak, D, Dustin, M, Dutertre, C-A, Ebner, F, Eckle, SBG, Edinger, M, Eede, P, Ehrhardt, GRA, Eich, M, Engel, P, Engelhardt, B, Erdei, A, Esser, C, Everts, B, Evrard, M, Falk, CS, Fehniger, TA, Felipo-Benavent, M, Ferry, H, Feuerer, M, Filby, A, Filkor, K, Fillatreau, S, Follo, M, Foerster, I, Foster, J, Foulds, GA, Frehse, B, Frenette, PS, Frischbutter, S, Fritzsche, W, Galbraith, DW, Gangaev, A, Garbi, N, Gaudilliere, B, Gazzinelli, RT, Geginat, J, Gerner, W, Gherardin, NA, Ghoreschi, K, Gibellini, L, Ginhoux, F, Goda, K, Godfrey, DI, Goettlinger, C, Gonzalez-Navajas, JM, Goodyear, CS, Gori, A, Grogan, JL, Grummitt, D, Gruetzkau, A, Haftmann, C, Hahn, J, Hammad, H, Haemmerling, G, Hansmann, L, Hansson, G, Harpur, CM, Hartmann, S, Hauser, A, Hauser, AE, Haviland, DL, Hedley, D, Hernandez, DC, Herrera, G, Herrmann, M, Hess, C, Hoefer, T, Hoffmann, P, Hogquist, K, Holland, T, Hollt, T, Holmdahl, R, Hombrink, P, Houston, JP, Hoyer, BF, Huang, B, Huang, F-P, Huber, JE, Huehn, J, Hundemer, M, Hunter, CA, Hwang, WYK, Iannone, A, Ingelfinger, F, Ivison, SM, Jaeck, H-M, Jani, PK, Javega, B, Jonjic, S, Kaiser, T, Kalina, T, Kamradt, T, Kaufmann, SHE, Keller, B, Ketelaars, SLC, Khalilnezhad, A, Khan, S, Kisielow, J, Klenerman, P, Knopf, J, Koay, H-F, Kobow, K, Kolls, JK, Kong, WT, Kopf, M, Korn, T, Kriegsmann, K, Kristyanto, H, Kroneis, T, Krueger, A, Kuehne, J, Kukat, C, Kunkel, D, Kunze-Schumacher, H, Kurosaki, T, Kurts, C, Kvistborg, P, Kwok, I, Landry, J, Lantz, O, Lanuti, P, LaRosa, F, Lehuen, A, LeibundGut-Landmann, S, Leipold, MD, Leung, LYT, Levings, MK, Lino, AC, Liotta, F, Litwin, V, Liu, Y, Ljunggren, H-G, Lohoff, M, Lombardi, G, Lopez, L, Lopez-Botet, M, Lovett-Racke, AE, Lubberts, E, Luche, H, Ludewig, B, Lugli, E, Lunemann, S, Maecker, HT, Maggi, L, Maguire, O, Mair, F, Mair, KH, Mantovani, A, Manz, RA, Marshall, AJ, Martinez-Romero, A, Martrus, G, Marventano, I, Maslinski, W, Matarese, G, Mattioli, AV, Maueroder, C, Mazzoni, A, McCluskey, J, McGrath, M, McGuire, HM, McInnes, IB, Mei, HE, Melchers, F, Melzer, S, Mielenz, D, Miller, SD, Mills, KHG, Minderman, H, Mjosberg, J, Moore, J, Moran, B, Moretta, L, Mosmann, TR, Mueller, S, Multhoff, G, Munoz, LE, Munz, C, Nakayama, T, Nasi, M, Neumann, K, Ng, LG, Niedobitek, A, Nourshargh, S, Nunez, G, O'Connor, J-E, Ochel, A, Oja, A, Ordonez, D, Orfao, A, Orlowski-Oliver, E, Ouyang, W, Oxenius, A, Palankar, R, Panse, I, Pattanapanyasat, K, Paulsen, M, Pavlinic, D, Penter, L, Peterson, P, Peth, C, Petriz, J, Piancone, F, Pickl, WF, Piconese, S, Pinti, M, Pockley, AG, Podolska, MJ, Poon, Z, Pracht, K, Prinz, I, Pucillo, CEM, Quataert, SA, Quatrini, L, Quinn, KM, Radbruch, H, Radstake, TRDJ, Rahmig, S, Rahn, H-P, Rajwa, B, Ravichandran, G, Raz, Y, Rebhahn, JA, Recktenwald, D, Reimer, D, Reis e Sousa, C, Remmerswaal, EBM, Richter, L, Rico, LG, Riddell, A, Rieger, AM, Robinson, JP, Romagnani, C, Rubartelli, A, Ruland, J, Saalmueller, A, Saeys, Y, Saito, T, Sakaguchi, S, Sala-de-Oyanguren, F, Samstag, Y, Sanderson, S, Sandrock, I, Santoni, A, Sanz, RB, Saresella, M, Sautes-Fridman, C, Sawitzki, B, Schadt, L, Scheffold, A, Scherer, HU, Schiemann, M, Schildberg, FA, Schimisky, E, Schlitzer, A, Schlosser, J, Schmid, S, Schmitt, S, Schober, K, Schraivogel, D, Schuh, W, Schueler, T, Schulte, R, Schulz, AR, Schulz, SR, Scotta, C, Scott-Algara, D, Sester, DP, Shankey, TV, Silva-Santos, B, Simon, AK, Sitnik, KM, Sozzani, S, Speiser, DE, Spidlen, J, Stahlberg, A, Stall, AM, Stanley, N, Stark, R, Stehle, C, Steinmetz, T, Stockinger, H, Takahama, Y, Takeda, K, Tan, L, Tarnok, A, Tiegs, G, Toldi, G, Tornack, J, Traggiai, E, Trebak, M, Tree, TIM, Trotter, J, Trowsdale, J, Tsoumakidou, M, Ulrich, H, Urbanczyk, S, van de Veen, W, van den Broek, M, van der Pol, E, Van Gassen, S, Van Isterdael, G, van Lier, RAW, Veldhoen, M, Vento-Asturias, S, Vieira, P, Voehringer, D, Volk, H-D, von Borstel, A, von Volkmann, K, Waisman, A, Walker, RV, Wallace, PK, Wang, SA, Wang, XM, Ward, MD, Ward-Hartstonge, KA, Warnatz, K, Warnes, G, Warth, S, Waskow, C, Watson, JV, Watzl, C, Wegener, L, Weisenburger, T, Wiedemann, A, Wienands, J, Wilharm, A, Wilkinson, RJ, Willimsky, G, Wing, JB, Winkelmann, R, Winkler, TH, Wirz, OF, Wong, A, Wurst, P, Yang, JHM, Yang, J, Yazdanbakhsh, M, Yu, L, Yue, A, Zhang, H, Zhao, Y, Ziegler, SM, Zielinski, C, Zimmermann, J, and Zychlinsky, A

Abstract

These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer-reviewed by leading experts in the field, making this an essential research companion.

Published
2019

34. Proteasome inhibition with bortezomib in SLE promotes therapeutically relevant depletion of short- and long-lived plasma cells but does not prevent their regeneration

Author

Alexander, T, Hoyer, BF, Klotsche, J, Cheng, Q, Taddeo, A, Kühl, AA, Burmester, GR, Radbruch, A, and Hiepe, F

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background: We previously identified long-lived plasma cells (PCs) are an essential component of the pathogenic immunologic memory, which is resistant to immunosuppressive and B cell depleting therapies and contributes to the chronicity of SLE. We recently demonstrated that their targeting with the [for full text, please go to the a.m. URL], 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2017
Full Text
View/download PDF

35. Neues Vaskulitisregister GeVas in Deutschland, Österreich und der Schweiz

Author

Lamprecht, P, Iking-Konert, C, Adler, S, de Groot, K, Hellmich, B, Hoyer, BF, Magnus, T, Rech, J, and Venhoff, N

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Vaskulitiden sind seltene Erkrankungen mit einer Prävalenz von unter 5 Erkrankten auf 10.000 Einwohner. Monozentrische Fallserien und Therapiestudien bilden das Diagnosespektrum, Organbeteiligungen und Outcome-Parameter wie das Ansprechen auf verschiedene Therapieregime, Organschäden,[zum vollständigen Text gelangen Sie über die oben angegebene URL], 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2017
Full Text
View/download PDF

36. First evidence of antigen-specific plasma cell depletion in vivo by an affinity matrix

Author

Cheng, Q, Pelz, A, Taddeo, A, Khodadadi, L, Hoyer, BF, Radbruch, A, and Hiepe, F

Subjects
selective depletion, ddc: 610, 610 Medical sciences, Medicine, affinity matrix, plasma cells
Abstract

Background: Since both short-lived and long-lived plasma cells are demonstrated to contribute to the pathogenesis of antibody-mediated diseases, they should be considered as a promising therapeutic target. Short-lived plasma cells respond to immunosuppressive drug treatments and B-cell targeted therapies,[for full text, please go to the a.m. URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2016
Full Text
View/download PDF

37. Lamina propria of the small intestine provides survival niches for memory plasma cells

Author

Lammerding, D, Cheng, Q, Kraft, M, Pollok, K, Khodadadi, L, Taddeo, A, Radbruch, A, Hiepe, F, Hauser, A, and Hoyer, BF

Subjects
ddc: 610, SLE, 610 Medical sciences, Medicine, mucosa, plasma cells
Abstract

Background: Autoreactive long-lived plasma cells (PCs) have been shown to play a major role in the pathogenesis of systemic lupus erythematosus, the prototype of systemic autoimmunity. Lymphatic organs such as spleen and bone marrow as well as inflamed organs such as inflamed kidneys have been shown[for full text, please go to the a.m. URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2016
Full Text
View/download PDF

38. B cell and Plasma cell homing in inflamed kidneys of lupus prone NZB/W mice is mediated differentially

Author

Hoyer, BF, Taddeo, A, Cheng, Q, Manz, R, Rudolph, B, Burmester, GR, and Hiepe, F

Subjects
ddc: 610, immune system diseases, urogenital system, 610 Medical sciences, Medicine, skin and connective tissue diseases
Abstract

Introduction: NZB/W mice spontaneously develop a lupus-like disease leading to lethal kidney failure due to nephritis. This disease manifestation is accompanied by inflammatory infiltration of the kidneys by lymphocytes. Which mechanisms lead to this kidney infiltrates and whether these might be[for full text, please go to the a.m. URL], 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2015
Full Text
View/download PDF

40. Antigen-specific depletion of autoantibody-secreting plasma cells

Author

Taddeo, A, Hoyer, BF, Gerl, V, Chang, HD, Pelz, A, Köhler, S, Thiel, A, Radbruch, A, and Hiepe, F

Subjects
Plasma cells, ddc: 610, Autoimmune diseases, Therapeutic depletion, 610 Medical sciences, Medicine, New therapies
Abstract

Background: Long-lived memory plasma cells (PCs) are an unmet therapeutic target in autoimmune diseases. Researchers have expanded their effort to develop new therapies to eliminate these cells. However, the current therapeutic options target the whole long-lived memory PC pool, depleting also PCs secreting[for full text, please go to the a.m. URL], 42. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 28. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 24. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2014
Full Text
View/download PDF

44. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus.

Author

Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, Burmester GR, Hiepe F, Dörner T, Jacobi, A M, Mei, H, Hoyer, B F, Mumtaz, I M, Thiele, K, Radbruch, A, Burmester, G-R, Hiepe, F, and Dörner, T

Abstract

Objectives: Monitoring of peripheral B-cell subsets in patients with systemic lupus erythematosus (SLE) revealed an activity-related expansion of CD27(++)CD20(-)CD19(dim) Ig-secreting cells. A similar subset has also been identified 6-8 days after tetanus/diphtheria vaccination in normal individuals and in patients with infectious disease.Methods: This subset was analysed further focussing on the HLA-DR surface expression in a cohort of 25 patients with SLE.Results: This study revealed that 86% (range 59-97%) of CD27(++)CD20(-)CD19(dim) cells express high levels of HLA-DR, are also expanded in the bone marrow, and represent plasmablasts enriched with anti-dsDNA secreting cells. The remaining CD27(++)CD20(-)CD19(dim) cells were HLA-DR(low) and represent mature plasma cells. Importantly, HLA-DR(high) plasmablasts showed a closer correlation with lupus activity and anti-dsDNA levels than the previously identified CD27(++)CD20(-)CD19(dim) cells.Conclusion: HLA-DR(high)CD27(++)CD20(-)CD19(dim) plasmablasts represent a more precise indicator of lupus activity and suggest that there is an overproduction or lack of negative selection of these cells in SLE. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

46. [Corona vaccination under immunosuppression].

Author

Hasseli-Fräbel R, Kneitz C, Voll RE, and Hoyer BF

Subjects
Humans, SARS-CoV-2 immunology, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Treatment Outcome, Evidence-Based Medicine, COVID-19 prevention & control, COVID-19 immunology, COVID-19 Vaccines adverse effects, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, Rheumatic Diseases immunology, Rheumatic Diseases drug therapy
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to play a major role as a severe and potentially fatal airway infection, especially in vulnerable patient groups. In view of the thin data situation on the influence of treatment and response to vaccination, at the beginning of the corona pandemic it was a major challenge to predict the tolerability and effectiveness in patients with inflammatory rheumatic diseases under immunomodulation or immunosuppression. In the meantime, numerous studies have addressed the questions of response and tolerability, at least for the COVID-19 vaccination. Even in the first months of the vaccination campaign, a small study on a single center cohort could show that apart from patients with B‑cell depletion, all included patients showed a seroconversion after the first two vaccinations. This resulted in neither an increased occurrence of exacerbations of the underlying disease nor new autoimmune phenomena. Various studies have since then confirmed these data., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

Published
2024
Full Text
View/download PDF

47. Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination.

Author

Buhre JS, Pongracz T, Geisen UM, Schubert M, Wang W, Nouta J, Obara M, Lehrian S, Rahmöller J, Petry J, Tran F, Schreiber S, Sümbül M, Berner D, Gerdes S, Schirmer J, Longardt AC, Hoff P, Kalinke U, Ludwig RJ, Bartsch YC, Hoyer BF, Wuhrer M, and Ehlers M

Abstract

Background: Recently, it has been questioned whether vaccination of patients with inflammatory (auto)immune diseases under anti-tumor necrosis factor (TNF) treatment leads to impaired vaccine-induced immune responses and protection against breakthrough infections. However, the effects of TNF blockade on short- and long-term immune responses after repeated vaccination remain unclear. Vaccination studies have shown that initial short-term IgG antibodies (Abs) carry highly galactosylated and sialylated Fc glycans, whilst long-term IgG Abs have low levels of galactosylation and sialylation and are most likely generated by long-lived plasma cells (PCs) derived primarily from the germinal center (GC) response. Thus, IgG Fc glycosylation patterns may be applicable to distinguish short- and long-term vaccine responses after repeated vaccination under the influence of anti-TNF treatment., Methods: We used COVID-19 vaccination as a model to investigate vaccine-induced IgG subclass levels and Fc glycosylation patterns, B cell subsets, and effector functions of short- and long-term Ab responses after up to three vaccinations in patients on anti-TNF or other immunosuppressive treatments and in healthy individuals. Using TriNetX, a global healthcare database, we determined the risk of SARS-CoV-2 breakthrough infections in vaccinated patients treated with anti-TNF or other immunosuppressive drugs., Results: Anti-TNF treatment reduced the long-term abundance of all anti-S IgG subclasses with low levels of galactosylation and sialylation. Re-activation of potential memory B cells initially generated highly galactosylated and sialylated IgG antibodies, which were progressively reduced after each booster dose in anti-TNF-treated patients, especially in the elderly. The reduced short- and long-term IgG (1) levels in anti-TNF-treated patients correlated with diminished functional activity and an increased risk for the development of COVID-19., Conclusions: The data suggest that anti-TNF treatment reduces both GC-dependent long-lived PCs and GC-dependent memory B cell-derived short-lived PCs, hence both the long- and short-term IgG subclass responses, respectively, after repeated vaccination. We propose that anti-TNF therapy, especially in the elderly, reduces the benefit of booster vaccination., (© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

48. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 GCA patients.

Author

Wallmeier P, Arnold S, Tais A, Ihorst G, Janoschke M, Schubach F, Aries P, Bergner R, Bremer JP, Görl N, Gutdeutsch E, Hellmich B, Henes J, Hoyer BF, Kangowski A, Kötter I, Krusche M, Magnus T, Metzler C, Müller-Ladner U, Schaier M, Schönermarck U, Thiel J, Unger L, Venhoff N, Weinmann-Menke J, Petersen J, Lamprecht P, and Iking-Konert C

Subjects
Humans, Male, Female, Aged, Aged, 80 and over, Prospective Studies, Germany epidemiology, Treatment Outcome, Time Factors, Recurrence, Registries, Giant Cell Arteritis drug therapy, Giant Cell Arteritis epidemiology, Giant Cell Arteritis diagnosis, Immunosuppressive Agents therapeutic use
Abstract

Objectives: Giant cell arteritis (GCA) is one of the most common forms of vasculitis. There is an abundance of studies which are conducted in a randomised controlled trial setting but limited with respect to cohort size and follow-up time. GeVas is the first large-scale registry for vasculitides in German-speaking countries that enables to evaluate this rare disease. Herein we focus on the subgroup of GCA patients including follow-up data up to one year., Methods: GeVas is a prospective, web-based, multicentre registry for the documentation of organ manifestations, outcomes, and therapy regimens in vasculitides. Recruitment started in June 2019. By April 2023, 15 centres were initiated and have started to enrol patients., Results: After 4 years, 195 GCA-patients were included in the registry, of which 64% were female and 36% were male. The average age was 76 years at the time of recruitment (IQR=69-82). Seventy-nine percent were included in the registry because of a newly diagnosed GCA and 21% because of a relapse. At the first assessment most of the patients (89%) described general symptoms. Thirty-one percent stated ocular symptoms. Cranial symptoms were documented in 78% of the cases. All patients were documented with immunosuppressive treatment at start, of whom 95% received prednisolone, 16% cyclophosphamide, 20% methotrexate, and 48% tocilizumab. After three months 62% and after one year 91% of the patients achieved remission., Conclusions: Regarding demographics, clinical manifestations and diagnostics, our study showed a similar composition compared to other studies. However, our data differed in terms of treatment regimens.

Published
2024
Full Text
View/download PDF

49. [Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy].

Author

Leipe J, Schmelz R, Riemekasten G, Thaçi D, Henes J, Schäkel K, Pinter A, Sticherling M, Wegner J, Fusco S, Linke M, Weber V, Manz KC, Bartz H, Roecken M, Schmidt S, and Hoyer BF

Subjects
Humans, Cross-Sectional Studies, Retrospective Studies, Immunomodulating Agents, Arthritis, Psoriatic, Arthritis, Rheumatoid, Psoriasis, Spondylarthritis therapy
Abstract

Background: Immune-mediated inflammatory diseases (IMID) can lead to a substantial disease burden for those affected, in particular by the concomitant occurrence of other IMIDs or in the presence of comorbidities. The care of patients with IMIDs is complex and involves various medical disciplines., Objective: To describe the burden of disease and the current routine drug treatment of patients with IMID., Material and Methods: The retrospective cross-sectional analysis was based on statutory health insurance claims data from the InGef database. Prevalent patients with psoriasis (Pso), psoriatic arthritis (PsA), spondylarthritis (SpA), rheumatoid arthritis (RA), Crohn's disease (MC), ulcerative colitis (CU), or connective tissue disease were identified among 3,988,695 insured patients in 2018. The concomitant occurrence of different IMIDs and the extent to which patients with IMID are affected by other comorbidities compared to a reference population were investigated. The current routine drug treatment was described based on the use of predefined forms of treatment., Results: In the database 188,440 patients with IMID (4.7%) were identified. Compared to the reference population the prevalence of comorbidities, such as depressive episodes and cardiovascular risk factors was higher in patients with IMID. For MC, CU, RA, and PsA disease-modifying antirheumatic drugs (DMARD) and classical systemic forms of treatment were used most commonly. In Pso, SpA, and connective tissue disease nonsteroidal anti-inflammatory drugs (NSAID) were the most frequently used treatment often in combination with other drugs., Conclusion: A considerable number of patients with IMIDs (16.9-27.5%) suffer from different diseases of the IMID group. They are frequently affected by accompanying illnesses and require interdisciplinary medical treatment., (© 2022. The Author(s).)

Published
2024
Full Text
View/download PDF

50. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 266 AAV patients.

Author

Arnold S, Wallmeier P, Tais A, Ihorst G, Janoschke M, Schubach F, Aries P, Bergner R, Bremer JP, Görl N, Gutdeutsch E, Hellmich B, Henes J, Hoyer BF, Kangowski A, Kötter I, Krusche M, Magnus T, Metzler C, Müller-Ladner U, Petersen J, Reichelt de Tenorio A, Schaier M, Schirmer JH, Schönermarck U, Thiel J, Unger L, Venhoff N, Weinmann-Menke J, Iking-Konert C, and Lamprecht P

Subjects
Humans, Female, Middle Aged, Male, Aged, Prospective Studies, Germany epidemiology, Immunosuppressive Agents therapeutic use, Treatment Outcome, Granulomatosis with Polyangiitis drug therapy, Granulomatosis with Polyangiitis epidemiology, Granulomatosis with Polyangiitis diagnosis, Granulomatosis with Polyangiitis immunology, Granulomatosis with Polyangiitis therapy, Recurrence, Microscopic Polyangiitis epidemiology, Microscopic Polyangiitis drug therapy, Microscopic Polyangiitis diagnosis, Microscopic Polyangiitis therapy, Microscopic Polyangiitis immunology, Churg-Strauss Syndrome epidemiology, Churg-Strauss Syndrome drug therapy, Churg-Strauss Syndrome diagnosis, Churg-Strauss Syndrome immunology, Disease Progression, Time Factors, Rituximab therapeutic use, Registries, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis epidemiology, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis therapy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis diagnosis
Abstract

Objectives: Prospective long-term observational data on the disease course of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were missing in Germany to date. Therefore, the Joint Vasculitis Registry in German-speaking countries (GeVas) has been established to follow the course of patients with AAV. The aim of this study is to present baseline data of patients with newly diagnosed and relapsing AAV enrolled in the GeVas registry., Methods: GeVas is a prospective, web-based, multicentre, clinician-driven registry for the documentation of organ manifestations, damage, long-term outcomes, and therapy regimens in various types of vasculitis. Recruitment started in June 2019., Results: Between June 2019 and October 2022, 266 patients with AAV were included in the GeVas registry: 173 (65%) with new-onset and 93 (35%) with relapsing AAV. One hundred and sixty-two (61%) patients were classified as granulomatosis with polyangiitis (GPA), 66 (25%) as microscopic polyangiitis (MPA), 36 (13%) as eosinophilic granulomatosis with polyangiitis (EGPA), and 2 (1%) as renal limited AAV. The median age was 59 years (51-70 years, IQR), 130 (51%) patients were female. Most patients were ANCA positive (177; 67%) and affected by general symptoms, pulmonary, ear nose throat (ENT), renal and neurological involvement. For induction of remission, the majority of patients received glucocorticoids (247, 93%) in combination with either rituximab (118, 45%) or cyclophosphamide (112, 42%)., Conclusions: Demographic characteristics are comparable to those in other European countries. Differences were found regarding ANCA status, frequencies of organ manifestations, and therapeutic regimens. The GeVas registry will allow longitudinal observations and prospective outcome measures in AAV.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results